The Latest Breaking News from melanoma

Cancer has become the modern-day plague with more and more people being diagnosed with the disease. Scientists have found a new treatment to kill tumours shows great promise in one trial

In a new study, researchers found that your gut microbiome can have a significant influence on your gut microbiome and the development of cancer.

Stephen Wadey was diagnosed with melanoma seven years ago. After surgery to remove the cancer, he decided to join a clinical trial — despite the huge distance.

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Kelsie Dummètt has had 21 early-stage melanomas and abnormal moles removed, with specialists unsure whether there's a link to her auto-immune condition.

"For some of the patients, it was like the tumours were frozen in time and they stayed the same for a very long time," Professor Bowden said. "

Because tumors grow rapidly and require lots of nutrition, scientists have been investigating ways to starve cancer cells.

Melanoma is the fifth most common cancer in the UK and the number of people diagnosed with the condition has increased over the last few decades.

Scientists have shown for the first time that inhibiting a key metabolic enzyme ‘shows promise’ in killing melanoma cells

Research could lead to a new class of drugs to selectively treat melanoma

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…